Multi-Society Guideline on Cytoreductive Surgery and HIPEC: Methodology and Overview of the Results

Front

1 of 3 · Front

📘 GuidelineCh 1 · Colorectal, Anorectal & Pilonidal Disease

Multi-Society Guideline on Cytoreductive Surgery and HIPEC: Methodology and Overview of the Results

In one breath

The multi-society CRS/HIPEC guideline's methodology and overview paper: seven recommendations built by GRADE ADOLOPMENT — conditional for metachronous colorectal and gastric peritoneal metastases, strong for pseudomyxoma, peritoneal mesothelioma and advanced ovarian cancer after neoadjuvant chemotherapy.

Edition2024

Issued byPSOGI with the European Society of Surgical Oncology, ERN-EURACAN, the Society of Surgical Oncology and partner societies (14 countries)

Place of issueInternational

PublishedJournal of Surgical Oncology · 2024;130(6):1173–1177

⏳ Pending verification

FACE COLOURS Front — the summary · Back 1 — what it covers + key recommendations · Back 2 — evidence, changes + source

Back 1

2 of 3 · Back 1

Back colours mark the reading sections — the chapter colour is the band and chip.

§1 · What it covers

This guideline covers adults with peritoneal surface malignancy across colorectal, gastric, pseudomyxoma, mesothelioma, and epithelial ovarian settings.

Applies to: Adults with peritoneal surface malignancy across colorectal, gastric, pseudomyxoma, mesothelioma, and epithelial ovarian settings.

§2 · Key recommendations

Seven recommendations were developed using GRADE ADOLOPMENT.
The panel confirmed conditional CRS/HIPEC recommendations for metachronous colorectal and gastric peritoneal metastases and strong recommendations for pseudomyxoma peritonei, peritoneal mesothelioma, and advanced epithelial ovarian cancer after neoadjuvant chemotherapy.
Prevention of peritoneal metastasis in high-risk colorectal cancer and platinum-sensitive ovarian recurrence remained uncertain or equipoise areas.

FACE COLOURS Front — the summary · Back 1 — what it covers + key recommendations · Back 2 — evidence, changes + source

Back 2

3 of 3 · Back 2

Back colours mark the reading sections — the chapter colour is the band and chip.

§3 · Evidence & grading

Seven panels, 28 professionals, seven societies. GRADE ADOLOPMENT explicitly incorporated certainty, patient values/preferences, resource use, accessibility, feasibility, and health equity. Strong recommendation required 80% majority; direction required simple majority.

§4 · What changed in this edition

Not yet established — pending verification.

§5 · Source & working link

Cinquini M, et al. Multi-Society Guideline on Cytoreductive Surgery and HIPEC: Methodology and Overview of the Results. J Surg Oncol. 2024;130(6):1173–1177. doi:10.1002/jso.27991 · PMID 39689044.

Publisher — the record's original_url, carried verbatim ↗DOI — 10.1002/jso.27991 ↗PubMed — PMID 39689044 ↗

Link check 2026-11-11: the DOI resolved at Crossref and the PubMed record (PMID 39689044, from the record's identifier field) was fetched live — both match this guideline's title, journal, volume and pages. The record's original_url fetched HTTP 200 but resolves to a DIFFERENT guideline (the ESMO sarcoma guideline page), not to this paper — a source-record error, flagged here and carried verbatim per spec; rely on the DOI/PubMed rows. Two of the record's listed PubMed links belong to that other guideline and are not carried.

Source: Tamer-supplied guideline index, intake 2026-11-10 (record #128, Domain 11) · Card built 2026-11-11 (Wave D) from the record itself; the §5.2 verification pass (UpToDate + Medscape → Perplexity → Tamer decision) has not yet run on this card. Completed in verification: pubmed row — PubMed PMID 39689044, fetched live 2026-11-11 — title, journal, volume and pages match. ⚑ Conflict flag on the source record — documented cross-society disagreement (intake DOCX Table 2): Colorectal peritoneal metastases — PSOGI HIPEC consensus 2022 vs ESMO/North American guidance in the post-PRODIGE-7 era. Unresolved — pending the verification pass (UpToDate + Medscape → Perplexity → Tamer decision).

FACE COLOURS Front — the summary · Back 1 — what it covers + key recommendations · Back 2 — evidence, changes + source

gl-div01-multisociety-crs-hipec-2024GS.code · Guidelines

More in Division 1 · Colorectal, Anorectal & Pilonidal Disease

📘 GuidelineCh 1 · Colorectal, Anorectal & Pilonidal Disease⏳ Pending verification

EAES-SAGES Clinical Practice Guideline Update: Multi-Society Recommendations on Key Controversies in the Management of Diverticular Disease

A multi-society update on the key controversies in diverticular disease: no routine antibiotics for uncomplicated diverticulitis, elective resection for persistent symptoms after recurrent episodes or recovery from a first abscess, and no routine follow-up colonoscopy after a first uncomplicated episode.

2026 Update · European Association for Endoscopic Surgery (EAES) and SAGES, with AAST, CSSANZ, EAST, ESCP, UEG and WSES participation

📘 GuidelineCh 1 · Colorectal, Anorectal & Pilonidal Disease⏳ Pending verification

2022 Peritoneal Surface Oncology Group International Consensus on HIPEC Regimens for Peritoneal Malignancies: Colorectal Cancer

The 2022 PSOGI consensus on HIPEC for colorectal peritoneal metastases: after complete cytoreductive surgery, HIPEC is conditionally recommended despite the negative PRODIGE-7 results — with short-duration high-dose oxaliplatin strongly rejected and mitomycin-C weakly favoured.

2022 Consensus · Peritoneal Surface Oncology Group International (PSOGI)

📘 GuidelineCh 1 · Colorectal, Anorectal & Pilonidal Disease⏳ Pending verification

INDEPSO-ISPSM Consensus on Peritoneal Malignancies: Management of Colorectal Peritoneal Metastases

The INDEPSO-ISPSM consensus on colorectal peritoneal metastases, written for Indian epidemiology and access: cytoreductive surgery for selected isolated or resectable disease, adjuvant systemic chemotherapy after CRS, and HIPEC outside trials only selectively — particularly at PCI 11–15.

2024 · Indian Network for Development of Peritoneal Surface Oncology (INDEPSO) and Indian Society of Peritoneal Surface Malignancies (ISPSM)